title: Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal.
authors: Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors: S Z
authors: SZ
authors: Usmani
authors: A
authors: A
authors: Hoering
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D009842:Oligopeptides / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D009842:Oligopeptides; C524865:carfilzomib